Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | PPARG | P37231 | 7/20 | 0.32 |
| ▸ | PPARD | Q03181 | 7/20 | 0.32 |
| ▸ | PPARA | Q07869 | 7/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL7647374 | 0.91 | PHF8 (0.41) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Metformin SCHEMBL1558869 | 0.91 | PHF8 (0.41) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Metformin SCHEMBL7123890 | 0.89 | PHF8 (0.39) | KDM7APHF8KDM2AKDM4C | |
| Adipic Acid SCHEMBL2812145 | 0.87 | LMNA (0.41) | AKR1B1GPR84PPARGPPARDPPARA | |
| Metformin SCHEMBL2815209 | 0.87 | SLC22A6 (0.41) | HDAC3HDAC1HDAC2HDAC8AKR1B1 | |
| Metformin SCHEMBL991100 | 0.87 | FFAR3 (0.40) | FFAR3 | |
| Dodecanoate SCHEMBL6051694 | 0.87 | GPR84 (0.53) | AKR1B1GPR84PPARGPPARDPPARA | |
| Decanoic Acid SCHEMBL6051781 | 0.87 | GPR84 (0.53) | AKR1B1GPR84PPARGPPARDPPARA | |
| Stearic Acid SCHEMBL6129908 | 0.87 | GPR84 (0.53) | AKR1B1GPR84PPARGPPARDPPARA | |
| Palmitic Acid SCHEMBL6051750 | 0.87 | GPR84 (0.53) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020139300-A2 | A COMBINATION COMPRISING GRANULOCYTE COLONY STIMULATING FACTOR | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2020-07-02 | — | — | WO | claimed |
| US-20120135952-A1 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2012-05-31 | — | — | US | claimed |
| US-20220002396-A1 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3873469-A2 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113286591-A | Methods of treating cancer with farnesyl transferase inhibitors | 库拉肿瘤学公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020139300-A2 | A COMBINATION COMPRISING GRANULOCYTE COLONY STIMULATING FACTOR | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2020-07-02 | — | — | WO | disclosed |
| US-20120135952-A1 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2012-05-31 | — | — | US | disclosed |
| US-20120135952-A1 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2012-05-31 | — | — | US | disclosed |
| WO-2011008054-A3 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | 한올바이오파마주식회사 (KR) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011008054-A2 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | 한올바이오파마주식회사 (KR) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135952-A1 | BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME | DDC, THEM6, ODC1 | FFAR3 1359/4885HDAC3 1159/4885HDAC1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.